PharmacovigilanceOfficial

FDA warns Florida clinical investigator over consent failings in INSTI HIV self-test study

🇺🇸 FDA CBER · Fri 20 Nov 2026

CBER's warning letter cites informed consent, unapproved consent-form changes and weak oversight at a site running bioLytical's CLS-003 study; the investigator did not respond to the Form 483.

The US Food and Drug Administration's Center for Biologics Evaluation and Research has issued a warning letter, dated 27 August 2026, to Stephen J. Fallon, Ph.D., of Wilton Manors, Florida. It follows a Bioresearch Monitoring inspection of his clinical study site between 2 and 13 June 2025. The study was Protocol CLS-003, evaluating the performance, usability and result interpretation of the INSTI HIV Self-Test among observed intended users in the US.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.